It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing
Digital prowess drives this Kansas City-based agency toward the $100-million mark
Going deeper with existing clients
Reinventing to offer more to clients
A transition year wrought rejuvenation
A market-specific approach resonates
Hello, Chicago! says an Austin agency
Diversifying breeds happiness
Evolving from a digitally focused shop into a full-service agency
Efforts to diversify roster
Looking at pharma from the inside out
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.